XML 91 R77.htm IDEA: XBRL DOCUMENT v3.6.0.2
Note 17 - Acquisition Activity (Details Textual) - USD ($)
3 Months Ended 12 Months Ended
Oct. 12, 2016
Jul. 01, 2016
Jul. 31, 2014
Dec. 31, 2016
Dec. 31, 2016
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Goodwill       $ 3,822,000 $ 3,822,000 $ 3,822,000 $ 45,000 $ 50,000
Payments to Acquire Businesses, Net of Cash Acquired           27,515,000 1,716,000
Goodwill, Impairment Loss           43,000    
GoutiFind Assay [Member]                
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)         270,000      
GoutiFind Assay [Member]                
Contingent Consideration Arrangements, Liability, Write-off         901,000      
SpiroFind Assay [Member]                
Contingent Consideration Arrangements, Liability, Write-off         551,000      
Imugen [Member]                
Payments to Acquire Businesses, Gross   $ 22,200,000            
Business Combination, Portion of Purchase Price Held in Escrow   1,800,000            
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill   18,900,000            
Goodwill   $ 2,645,000            
Goodwill, Tax Deduction, Period   15 years            
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual           7,000,000    
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual           730,000    
Goodwill, Impairment Loss           0    
Imugen [Member] | In Process Research and Development, Indefinite Lived [Member]                
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill   $ 9,200,000            
Imugen [Member] | General and Administrative Expense [Member]                
Business Combination, Acquisition Related Costs           475,000    
Imugen [Member] | Intangible Assets [Member]                
Fair Value Inputs, Discount Rate   22.00%            
Immunetics [Member]                
Payments to Acquire Businesses, Gross $ 6,000,000              
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill 8,600,000              
Goodwill 1,177,000              
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual 392,000              
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual 813,000              
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High $ 6,000,000              
Business Combination, Contingent Consideration Arrangement, Term of Milestone Achievement 3 years              
Business Combination, Portion of Purchase Price Held for Indemnification Claims $ 400,000              
Business Combination, Contingent Consideration, Liability 3,400,000              
Goodwill, Impairment Loss       $ 0        
Immunetics [Member] | In Process Research and Development, Indefinite Lived [Member]                
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill $ 6,970,000              
Immunetics [Member] | Contingent Purchase Price Consideration [Member]                
Fair Value Inputs, Discount Rate 4.40%              
Immunetics [Member] | General and Administrative Expense [Member]                
Business Combination, Acquisition Related Costs $ 655,000              
Immunetics [Member] | Intangible Assets [Member] | Minimum [Member]                
Fair Value Inputs, Discount Rate 21.60%              
Immunetics [Member] | Intangible Assets [Member] | Maximum [Member]                
Fair Value Inputs, Discount Rate 60.20%              
Imugen and Immunetics [Member]                
Business Combination, Acquisition Related Costs and Accelerated Stock-based Compensation Costs           $ 2,700,000    
Boulder Diagnostics Inc [Member]                
Payments to Acquire Businesses, Gross     $ 1,724,000          
Goodwill     55,000          
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual               42,000
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual               $ 396,000
Business Combination, Contingent Consideration, Liability     1,200,000          
Payments to Acquire Businesses, Net of Cash Acquired     1,700,000          
Restricted Cash and Cash Equivalents     183,200          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets     $ 2,627,000          
Boulder Diagnostics Inc [Member] | In Process Research and Development Member 1 [Member]                
Fair Value Inputs, Discount Rate     15.00%          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets     $ 2,600,000          
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)             $ 385,000  
Boulder Diagnostics Inc [Member] | Lyme Disease Assay [Member]                
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets     1,800,000          
Boulder Diagnostics Inc [Member] | Biologics for Autoimmune Disease Assay [Member]                
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets     500,000          
Boulder Diagnostics Inc [Member] | Gout Assay [Member]                
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets     300,000          
Boulder Diagnostics Inc [Member] | In Process Research and Development, Indefinite Lived [Member]                
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)         $ 1,400,000      
Boulder Diagnostics Inc [Member] | Milestone Payments [Member]                
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High     6,100,000          
Boulder Diagnostics Inc [Member] | Milestone Payments for Completion of Studies Related to Acquired Technologies [Member]                
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High     400,000          
Boulder Diagnostics Inc [Member] | Milestone Payments for Development of Diagnostic Test Kits [Member]                
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High     700,000          
Boulder Diagnostics Inc [Member] | Milestone Payments for the First Patient Enrolled in an Institution Review Board Approved Study [Member]                
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High     500,000          
Boulder Diagnostics Inc [Member] | Milestone Payments for Issuance of Patents [Member]                
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High     1,500,000          
Boulder Diagnostics Inc [Member] | Milestone Payments for Approvals or Clearance by the FDA [Member}                
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High     3,000,000          
Boulder Diagnostics Inc [Member] | General and Administrative Expense [Member]                
Business Combination, Acquisition Related Costs     $ 181,000